134 related articles for article (PubMed ID: 37989136)
1. The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kommu S
J Cardiovasc Pharmacol; 2024 Feb; 83(2):158-166. PubMed ID: 37989136
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
Banerjee M; Maisnam I; Pal R; Mukhopadhyay S
Eur Heart J; 2023 Oct; 44(37):3686-3696. PubMed ID: 37605637
[TBL] [Abstract][Full Text] [Related]
3. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M; Abbasi MA; Al-Abcha A; El-Am E; Lundgren S; Goldsweig AM; Anavekar NS
Curr Probl Cardiol; 2023 May; 48(5):101597. PubMed ID: 36681210
[TBL] [Abstract][Full Text] [Related]
6. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
8. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
Täger T; Frankenstein L; Atar D; Agewall S; Frey N; Grundtvig M; Clark AL; Cleland JGF; Fröhlich H
Clin Res Cardiol; 2022 Apr; 111(4):428-439. PubMed ID: 34498169
[TBL] [Abstract][Full Text] [Related]
9. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
Li X; Zhang Q; Zhu L; Wang G; Ge P; Hu A; Sun X
Int J Cardiol; 2021 Jun; 332():119-126. PubMed ID: 33838152
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials.
Camilli M; Lombardi M; Chiabrando JG; Zito A; Del Buono MG; Vergallo R; Aspromonte N; Lombardo A; Montone RA; Niccoli G; Biondi-Zoccai G; Crea F; Minotti G
Am J Ther; 2021 Nov; 29(2):e199-e204. PubMed ID: 35389572
[TBL] [Abstract][Full Text] [Related]
11. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
Zheng S; Lai Y; Jiang C; He L; Zhao Z; Li W; Tang R; Sang C; Long D; Du X; Ma C; Dong J
Pacing Clin Electrophysiol; 2024 Jan; 47(1):58-65. PubMed ID: 38010824
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
Cao Y; Li P; Li Y; Han Y
ESC Heart Fail; 2022 Jun; 9(3):1942-1953. PubMed ID: 35338608
[TBL] [Abstract][Full Text] [Related]
13. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
[TBL] [Abstract][Full Text] [Related]
14. Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials.
Bazoukis G; Papadatos SS; Thomopoulos C; Tse G; Cheilidis S; Tsioufis K; Farmakis D
J Geriatr Cardiol; 2021 Oct; 18(10):783-795. PubMed ID: 34754290
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
[TBL] [Abstract][Full Text] [Related]
16. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
18. Safety of sodium-glucose cotransporter 2 inhibitors drugs among heart failure patients: a systematic review and meta-analysis.
Soleimani H; Saeedian B; Pasebani Y; Babajani N; Pashapour Yeganeh A; Bahirai P; Navid H; Amin A; Samsky MD; Nanna MG; Hosseini K
ESC Heart Fail; 2024 Apr; 11(2):637-648. PubMed ID: 38124239
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
Kumar K; Kheiri B; Simpson TF; Osman M; Rahmouni H
Am J Med; 2020 Nov; 133(11):e625-e630. PubMed ID: 32389659
[TBL] [Abstract][Full Text] [Related]
20. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
